KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment: 2018-2019

Historic Asset Writedowns and Impairment for Aquestive Therapeutics (AQST) over the last 1 years, with Sep 2019 value amounting to $6,000.

  • Aquestive Therapeutics' Asset Writedowns and Impairment fell 85.71% to $6,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $16,000, marking a year-over-year change of. This contributed to the annual value of $53,000 for FY2018, which is N/A change from last year.
  • According to the latest figures from Q3 2019, Aquestive Therapeutics' Asset Writedowns and Impairment is $6,000, which was down 75.00% from $24,000 recorded in Q2 2019.
  • Aquestive Therapeutics' 5-year Asset Writedowns and Impairment high stood at $42,000 for Q3 2018, and its period low was -$20,000 during Q4 2018.
  • In the last 2 years, Aquestive Therapeutics' Asset Writedowns and Impairment had a median value of $6,000 in 2019 and averaged $11,600.
  • Data for Aquestive Therapeutics' Asset Writedowns and Impairment shows a maximum YoY crashed of 85.71% (in 2019) over the last 5 years.
  • Quarterly analysis of 2 years shows Aquestive Therapeutics' Asset Writedowns and Impairment stood at -$20,000 in 2018, then plummeted by 85.71% to $6,000 in 2019.
  • Its Asset Writedowns and Impairment stands at $6,000 for Q3 2019, versus $24,000 for Q2 2019 and $6,000 for Q1 2019.